Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Psychologists warn about the dangers of rising psychological pseudoscience October 24, 2023 Everyday physical activity provides immediate benefits for brain health November 12, 2024 Machine learning sheds light on mental health challenges faced by HCWs during COVID-19 pandemic October 29, 2023
Machine learning sheds light on mental health challenges faced by HCWs during COVID-19 pandemic October 29, 2023